Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Closed versus open inhaled triple therapy in COPD (FF/UMEC/VI vs FF/VI + UMEC)
2015-005212-14Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in trough FEV1 at 24 weeks. Started Feb 2016; status: completed.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-005212-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005212-14.